Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015199 | 1.00 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2TYRO3CNR2 | |
| SCHEMBL1012283 | 0.99 | TYRO3 (0.54) | NPC1RAB9ASMN1; SMN2TYRO3CNR2 | |
| SCHEMBL1014954 | 0.88 | TYRO3 (0.53) | NPC1RAB9ASMN1; SMN2TYRO3HPGDS | |
| SCHEMBL1015521 | 0.88 | TYRO3 (0.53) | NPC1RAB9ASMN1; SMN2TYRO3HPGDS | |
| SCHEMBL1014913 | 0.87 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2TYRO3CNR2 | |
| SCHEMBL1015403 | 0.87 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2TYRO3CNR2 | |
| SCHEMBL1015261 | 0.87 | TYRO3 (0.54) | RAB9ASMN1; SMN2TYRO3HPGDSALDH1A1 | |
| SCHEMBL1013869 | 0.86 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2TYRO3CNR2 | |
| SCHEMBL1016069 | 0.82 | TYRO3 (0.69) | RAB9ATYRO3HPGDMEN1ALDH1A1 | |
| SCHEMBL1015098 | 0.81 | TYRO3 (0.70) | RAB9ATYRO3MEN1KMT2ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | NPC1 1075/4885RAB9A 1947/4885SMN1; SMN2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.